Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
- 2 June 2001
- journal article
- review article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 28 (11) , 1725-1735
- https://doi.org/10.1007/s002590100570
Abstract
In the past decade, several new antibody-based therapies – using either radiolabelled or unlabelled monoclonal antibodies – have become available for the treatment of patients with refractory or recurrent non-Hodgkin's lymphoma (NHL). Unlabelled monoclonal antibodies (mAbs) kill lymphoma cells by activating host immune effector mechanisms, or by inducing apoptosis. These mAbs can also be used to guide radionuclides to the lymphoma. This radioimmunotherapy (RIT) has been studied with various nuclides (131I, 90Y, 67Cu and 186Re) and with various mAbs. In this review the radionuclides, methods of dosing and recent RIT studies in patients with B-cell NHL are reviewed. Most of these studies demonstrate that RIT is an effective new treatment modality for NHL.Keywords
This publication has 0 references indexed in Scilit: